首页 > 最新文献

PLoS Medicine最新文献

英文 中文
Mechanism mapping to advance research on implementation strategies. 机制映射促进实施策略研究。
IF 15.8 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-02-08 eCollection Date: 2022-02-01 DOI: 10.1371/journal.pmed.1003918
Elvin H Geng, Ana A Baumann, Byron J Powell

Elvin Hsing Geng and colleagues discuss mechanism mapping and its utility in conceptualizing and understanding how implementation strategies produce desired effects.

Elvin Hsing Geng及其同事讨论了机制映射及其在概念化和理解实施策略如何产生预期效果方面的效用。
{"title":"Mechanism mapping to advance research on implementation strategies.","authors":"Elvin H Geng,&nbsp;Ana A Baumann,&nbsp;Byron J Powell","doi":"10.1371/journal.pmed.1003918","DOIUrl":"https://doi.org/10.1371/journal.pmed.1003918","url":null,"abstract":"<p><p>Elvin Hsing Geng and colleagues discuss mechanism mapping and its utility in conceptualizing and understanding how implementation strategies produce desired effects.</p>","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":"19 2","pages":"e1003918"},"PeriodicalIF":15.8,"publicationDate":"2022-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39603401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study 意大利12 - 39岁人群接种COVID-19 mRNA疫苗后心肌炎和心包炎上市后的主动监测:一项多数据库、自我控制的病例系列研究
IF 15.8 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-02-08 DOI: 10.1101/2022.02.07.22270020
M. Massari, S. Spila Alegiani, C. Morciano, M. Spuri, P. Marchione, P. Felicetti, V. Belleudi, F. Poggi, M. Lazzeretti, Michele Ercolanoni, E. Clagnan, E. Bovo, G. Trifirò, U. Moretti, G. Monaco, O. Leoni, R. Da Cas, F. Petronzelli, L. Tartaglia, N. Mores, G. Zanoni, P. Rossi, Sarah Samez, Cristina Zappetti, A. Marra, F. Menniti Ippolito
Objectives To investigate the association between SARS-CoV-2 mRNA vaccines, BNT162b2 and mRNA-1273, and myocarditis/pericarditis. Design Self-Controlled Case Series study (SCCS) using national data on COVID-19 vaccination and emergency care/hospital admissions. Setting Italian Regions (Lombardia, Friuli Venezia Giulia, Veneto, Lazio). Participants 2,861,809 individuals, aged 12-39 years, vaccinated with the first doses of mRNA vaccines (2,405,759 BNT162b2 and 456,050 mRNA-1273) between 27 December 2020 and 30 September 2021. Main outcome measures First diagnosis of myocarditis/pericarditis within the study period. The incidence of events in the exposure risk periods (0-21 days from the vaccination day, subdivided in three equal intervals) for first and second dose was compared with baseline period. The SCCS model was fitted using conditional Poisson regression to estimate Relative Incidences (RI) and Excess of Cases (EC) per 100,000 vaccinated by dose, age, gender and brand. Results During the study period, 441 participants aged 12-39 years developed myocarditis/pericarditis (346 BNT162b2 and 95 mRNA-1273). During the 21-day risk interval there were 114 cases of myocarditis/pericarditis (74 BNT162b2 and 40 mRNA-1273) corresponding to a RI of 1.27 (0.87-1.85) and 2.16 (1.50-3.10) after first and second dose, respectively. An increased risk of myocarditis/pericarditis at (0-7) days was observed after first [RI=6.55; 95% Confidence Interval (2.73-15.72); EC per 100,000 vaccinated=2.0 (1.5-2.3)] and second dose [RI=7.59 (3.26-17.65); EC=5.5 (4.4-5.9)] of mRNA-1273 and after second dose of BNT162b2 [RI=3.39 (2.02-5.68); EC=0.8 (0.6-1.0)]. In males, an increased risk at (0-7) days was observed after first [RI=12.28, 4.09-36.83; EC=3.8 (3.1-4.0)] and second dose [RI=11.91 (3.88-36.53); EC=8.8 (7.2-9.4)] of mRNA-1273 and after second dose of BNT162b2 [RI=3.45 (1.78-6.68); EC=1.0 (0.6-1.2)]. In females, an increased risk at (0-7) days was observed after second dose of BNT162b2 [RI=3.38 (1.47-7.74); EC=0.7 (0.3-0.9)]. At (0-7) days an increased risk following second dose of BNT162b2 was observed in the 12-17 years old [RI=5.74, (1.52-21.72); EC=1.7 (0.7-1.9)] and in 18-29 years old [RI=4.02 (1.81-8.91); EC=1.1 (0.6-1.3)]. At (0-7) days an increased risk after first [RI=7.58 (2.62-21.94); EC=3.5 (2.4-3.8)] and second [RI=9.58 (3.32-27.58); EC=8.3 (6.7-9.2)] dose of mRNA-1273 was found in 18-29 years old and after first dose in 30-39 years old [RI=6.57 (1.32-32.63); EC=1.0 (0.3-1.1)]. Conclusions This population-based study indicates that mRNA vaccines were associated with myocarditis/pericarditis in the population younger than 40 years, whereas no association was observed in older subjects. The risk increased after the second dose and in the youngest for both vaccines, remained moderate following vaccination with BNT162b2, while was higher in males following vaccination with mRNA-1273. The public health implication of these findings should be weighed in the
目的探讨SARS-CoV-2 mRNA疫苗、BNT162b2和mRNA-1273与心肌炎/心包炎的关系。使用COVID-19疫苗接种和急诊/住院的国家数据设计自控病例系列研究(SCCS)。设置意大利地区(伦巴第,弗留利,威尼斯朱利亚,威尼托,拉齐奥)。参与者2,861,809人,年龄在12-39岁之间,在2020年12月27日至2021年9月30日期间接种了第一剂mRNA疫苗(2,405,759 BNT162b2和456,050 mRNA-1273)。主要观察指标研究期间首次诊断心肌炎/心包炎。将第一次和第二次剂量暴露风险期(从接种疫苗日起0-21天,细分为三个相等间隔)的事件发生率与基线期进行比较。SCCS模型采用条件泊松回归拟合,以按剂量、年龄、性别和品牌估计每10万人接种疫苗的相对发病率(RI)和超额病例(EC)。结果在研究期间,441名年龄在12-39岁的参与者发生心肌炎/心包炎(346例BNT162b2和95例mRNA-1273)。在21天的危险间期,第一次和第二次给药后,有114例心肌炎/心包炎(74例BNT162b2和40例mRNA-1273),对应的RI分别为1.27(0.87-1.85)和2.16(1.50-3.10)。第一次治疗后(0-7)天发生心肌炎/心包炎的风险增加[RI=6.55;95%置信区间(2.73-15.72);每10万接种者EC =2.0(1.5-2.3)]和第二剂[RI=7.59 (3.26-17.65)];第二次给药BNT162b2后,EC=5.5 (4.4 ~ 5.9), RI=3.39 (2.02 ~ 5.68);电子商务= 0.8(0.6 - -1.0)]。在男性中,第一次发病后(0-7)天风险增加[RI=12.28, 4.09-36.83;EC=3.8(3.1-4.0)]和第二次剂量[RI=11.91 (3.88-36.53)];第二次给药BNT162b2后,EC=8.8 (7.2 ~ 9.4), RI=3.45 (1.78 ~ 6.68);电子商务= 1.0(0.6 - -1.2)]。在雌性中,第二次注射BNT162b2后(0-7)天的风险增加[RI=3.38 (1.47-7.74);电子商务= 0.7(0.3 - -0.9)]。在(0-7)天观察到12-17岁儿童在第二次给药BNT162b2后风险增加[RI=5.74, (1.52-21.72);EC=1.7(0.7 ~ 1.9), 18 ~ 29岁[RI=4.02 (1.81 ~ 8.91)];电子商务= 1.1(0.6 - -1.3)]。在(0-7)天,首次发病后风险增加[RI=7.58 (2.62-21.94);EC = 3.5(2.4 - -3.8)]和第二(RI = 9.58 (3.32 - -27.58);18 ~ 29岁和30 ~ 39岁首次给药后,出现了EC=8.3(6.7 ~ 9.2)的mRNA-1273剂量[RI=6.57 (1.32 ~ 32.63)];电子商务= 1.0(0.3 - -1.1)]。结论:这项基于人群的研究表明,mRNA疫苗与40岁以下人群的心肌炎/心包炎相关,而在老年受试者中未观察到相关。接种两种疫苗后,第二次接种后风险增加,接种BNT162b2疫苗后风险保持中等,而接种mRNA-1273疫苗后男性风险更高。这些发现对公共卫生的影响应根据这两种疫苗的总体有效性和安全性进行权衡。
{"title":"Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study","authors":"M. Massari, S. Spila Alegiani, C. Morciano, M. Spuri, P. Marchione, P. Felicetti, V. Belleudi, F. Poggi, M. Lazzeretti, Michele Ercolanoni, E. Clagnan, E. Bovo, G. Trifirò, U. Moretti, G. Monaco, O. Leoni, R. Da Cas, F. Petronzelli, L. Tartaglia, N. Mores, G. Zanoni, P. Rossi, Sarah Samez, Cristina Zappetti, A. Marra, F. Menniti Ippolito","doi":"10.1101/2022.02.07.22270020","DOIUrl":"https://doi.org/10.1101/2022.02.07.22270020","url":null,"abstract":"Objectives To investigate the association between SARS-CoV-2 mRNA vaccines, BNT162b2 and mRNA-1273, and myocarditis/pericarditis. Design Self-Controlled Case Series study (SCCS) using national data on COVID-19 vaccination and emergency care/hospital admissions. Setting Italian Regions (Lombardia, Friuli Venezia Giulia, Veneto, Lazio). Participants 2,861,809 individuals, aged 12-39 years, vaccinated with the first doses of mRNA vaccines (2,405,759 BNT162b2 and 456,050 mRNA-1273) between 27 December 2020 and 30 September 2021. Main outcome measures First diagnosis of myocarditis/pericarditis within the study period. The incidence of events in the exposure risk periods (0-21 days from the vaccination day, subdivided in three equal intervals) for first and second dose was compared with baseline period. The SCCS model was fitted using conditional Poisson regression to estimate Relative Incidences (RI) and Excess of Cases (EC) per 100,000 vaccinated by dose, age, gender and brand. Results During the study period, 441 participants aged 12-39 years developed myocarditis/pericarditis (346 BNT162b2 and 95 mRNA-1273). During the 21-day risk interval there were 114 cases of myocarditis/pericarditis (74 BNT162b2 and 40 mRNA-1273) corresponding to a RI of 1.27 (0.87-1.85) and 2.16 (1.50-3.10) after first and second dose, respectively. An increased risk of myocarditis/pericarditis at (0-7) days was observed after first [RI=6.55; 95% Confidence Interval (2.73-15.72); EC per 100,000 vaccinated=2.0 (1.5-2.3)] and second dose [RI=7.59 (3.26-17.65); EC=5.5 (4.4-5.9)] of mRNA-1273 and after second dose of BNT162b2 [RI=3.39 (2.02-5.68); EC=0.8 (0.6-1.0)]. In males, an increased risk at (0-7) days was observed after first [RI=12.28, 4.09-36.83; EC=3.8 (3.1-4.0)] and second dose [RI=11.91 (3.88-36.53); EC=8.8 (7.2-9.4)] of mRNA-1273 and after second dose of BNT162b2 [RI=3.45 (1.78-6.68); EC=1.0 (0.6-1.2)]. In females, an increased risk at (0-7) days was observed after second dose of BNT162b2 [RI=3.38 (1.47-7.74); EC=0.7 (0.3-0.9)]. At (0-7) days an increased risk following second dose of BNT162b2 was observed in the 12-17 years old [RI=5.74, (1.52-21.72); EC=1.7 (0.7-1.9)] and in 18-29 years old [RI=4.02 (1.81-8.91); EC=1.1 (0.6-1.3)]. At (0-7) days an increased risk after first [RI=7.58 (2.62-21.94); EC=3.5 (2.4-3.8)] and second [RI=9.58 (3.32-27.58); EC=8.3 (6.7-9.2)] dose of mRNA-1273 was found in 18-29 years old and after first dose in 30-39 years old [RI=6.57 (1.32-32.63); EC=1.0 (0.3-1.1)]. Conclusions This population-based study indicates that mRNA vaccines were associated with myocarditis/pericarditis in the population younger than 40 years, whereas no association was observed in older subjects. The risk increased after the second dose and in the youngest for both vaccines, remained moderate following vaccination with BNT162b2, while was higher in males following vaccination with mRNA-1273. The public health implication of these findings should be weighed in the","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":" ","pages":""},"PeriodicalIF":15.8,"publicationDate":"2022-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43116498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Estimating impact of food choices on life expectancy: A modeling study. 估计食物选择对预期寿命的影响:一项模型研究。
IF 15.8 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-02-08 eCollection Date: 2022-02-01 DOI: 10.1371/journal.pmed.1003889
Lars T Fadnes, Jan-Magnus Økland, Øystein A Haaland, Kjell Arne Johansson
<p><strong>Background: </strong>Interpreting and utilizing the findings of nutritional research can be challenging to clinicians, policy makers, and even researchers. To make better decisions about diet, innovative methods that integrate best evidence are needed. We have developed a decision support model that predicts how dietary choices affect life expectancy (LE).</p><p><strong>Methods and findings: </strong>Based on meta-analyses and data from the Global Burden of Disease study (2019), we used life table methodology to estimate how LE changes with sustained changes in the intake of fruits, vegetables, whole grains, refined grains, nuts, legumes, fish, eggs, milk/dairy, red meat, processed meat, and sugar-sweetened beverages. We present estimates (with 95% uncertainty intervals [95% UIs]) for an optimized diet and a feasibility approach diet. An optimal diet had substantially higher intake than a typical diet of whole grains, legumes, fish, fruits, vegetables, and included a handful of nuts, while reducing red and processed meats, sugar-sweetened beverages, and refined grains. A feasibility approach diet was a midpoint between an optimal and a typical Western diet. A sustained change from a typical Western diet to the optimal diet from age 20 years would increase LE by more than a decade for women from the United States (10.7 [95% UI 8.4 to 12.3] years) and men (13.0 [95% UI 9.4 to 14.3] years). The largest gains would be made by eating more legumes (females: 2.2 [95% UI 1.1 to 3.4]; males: 2.5 [95% UI 1.1 to 3.9]), whole grains (females: 2.0 [95% UI 1.3 to 2.7]; males: 2.3 [95% UI 1.6 to 3.0]), and nuts (females: 1.7 [95% UI 1.5 to 2.0]; males: 2.0 [95% UI 1.7 to 2.3]), and less red meat (females: 1.6 [95% UI 1.5 to 1.8]; males: 1.9 [95% UI 1.7 to 2.1]) and processed meat (females: 1.6 [95% UI 1.5 to 1.8]; males: 1.9 [95% UI 1.7 to 2.1]). Changing from a typical diet to the optimized diet at age 60 years would increase LE by 8.0 (95% UI 6.2 to 9.3) years for women and 8.8 (95% UI 6.8 to 10.0) years for men, and 80-year-olds would gain 3.4 years (95% UI females: 2.6 to 3.8/males: 2.7 to 3.9). Change from typical to feasibility approach diet would increase LE by 6.2 (95% UI 3.5 to 8.1) years for 20-year-old women from the United States and 7.3 (95% UI 4.7 to 9.5) years for men. Using NutriGrade, the overall quality of evidence was assessed as moderate. The methodology provides population estimates under given assumptions and is not meant as individualized forecasting, with study limitations that include uncertainty for time to achieve full effects, the effect of eggs, white meat, and oils, individual variation in protective and risk factors, uncertainties for future development of medical treatments; and changes in lifestyle.</p><p><strong>Conclusions: </strong>A sustained dietary change may give substantial health gains for people of all ages both for optimized and feasible changes. Gains are predicted to be larger the earlier the dietary chan
背景:对临床医生、政策制定者甚至研究人员来说,解释和利用营养研究的发现可能是一项挑战。为了对饮食做出更好的决定,需要结合最佳证据的创新方法。我们开发了一个决策支持模型来预测饮食选择如何影响预期寿命。方法和发现:基于全球疾病负担研究(2019年)的荟萃分析和数据,我们使用生命表方法来估计LE如何随着水果、蔬菜、全谷物、精制谷物、坚果、豆类、鱼、鸡蛋、牛奶/乳制品、红肉、加工肉类和含糖饮料摄入量的持续变化而变化。我们提出了优化日粮和可行性方法日粮的估计(95%不确定区间[95% u])。最理想的饮食要比典型的全谷物、豆类、鱼类、水果、蔬菜的摄入量高得多,并包括少量坚果,同时减少红肉和加工肉类、含糖饮料和精制谷物。可行性方法饮食是介于最佳饮食和典型西方饮食之间的中点。从20岁开始,从典型的西方饮食持续改变到最佳饮食,将使美国女性(10.7 [95% UI 8.4 - 12.3]年)和男性(13.0 [95% UI 9.4 - 14.3]年)的LE增加10年以上。多吃豆类会获得最大的收益(女性:2.2 [95% UI 1.1至3.4];男性:2.5 [95% UI 1.1至3.9]),全谷物(女性:2.0 [95% UI 1.3至2.7];雄性:2.3 [95% UI 1.6至3.0])和坚果(雌性:1.7 [95% UI 1.5至2.0];男性:2.0 [95% UI为1.7至2.3]),少吃红肉(女性:1.6 [95% UI为1.5至1.8];男性:1.9 [95% UI 1.7至2.1])和加工肉类(女性:1.6 [95% UI 1.5至1.8];男性:1.9 [95% UI为1.7至2.1])。60岁时从典型饮食改为优化饮食,女性寿命增加8.0 (95% UI为6.2 ~ 9.3)年,男性寿命增加8.8 (95% UI为6.8 ~ 10.0)年,80岁时寿命增加3.4年(95% UI为女性:2.6 ~ 3.8/男性:2.7 ~ 3.9)。从典型饮食到可行性饮食的改变将使美国20岁女性的寿命增加6.2年(95% UI为3.5至8.1)年,男性的寿命增加7.3年(95% UI为4.7至9.5)年。使用NutriGrade,证据的总体质量被评估为中等。该方法提供了在给定假设下的人口估计,而不是作为个人预测,研究的局限性包括实现充分效果的时间的不确定性,鸡蛋、白肉和油的影响,保护和风险因素的个体差异,未来医疗发展的不确定性;生活方式的改变。结论:持续的饮食改变可以为所有年龄段的人带来实质性的健康收益,无论是优化的还是可行的改变。据预测,饮食改变在生命中越早开始,收益就越大。我们在网上提供的Food4HealthyLife计算器可以帮助临床医生、政策制定者和非专业人士了解饮食选择对健康的影响。
{"title":"Estimating impact of food choices on life expectancy: A modeling study.","authors":"Lars T Fadnes,&nbsp;Jan-Magnus Økland,&nbsp;Øystein A Haaland,&nbsp;Kjell Arne Johansson","doi":"10.1371/journal.pmed.1003889","DOIUrl":"https://doi.org/10.1371/journal.pmed.1003889","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Interpreting and utilizing the findings of nutritional research can be challenging to clinicians, policy makers, and even researchers. To make better decisions about diet, innovative methods that integrate best evidence are needed. We have developed a decision support model that predicts how dietary choices affect life expectancy (LE).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods and findings: &lt;/strong&gt;Based on meta-analyses and data from the Global Burden of Disease study (2019), we used life table methodology to estimate how LE changes with sustained changes in the intake of fruits, vegetables, whole grains, refined grains, nuts, legumes, fish, eggs, milk/dairy, red meat, processed meat, and sugar-sweetened beverages. We present estimates (with 95% uncertainty intervals [95% UIs]) for an optimized diet and a feasibility approach diet. An optimal diet had substantially higher intake than a typical diet of whole grains, legumes, fish, fruits, vegetables, and included a handful of nuts, while reducing red and processed meats, sugar-sweetened beverages, and refined grains. A feasibility approach diet was a midpoint between an optimal and a typical Western diet. A sustained change from a typical Western diet to the optimal diet from age 20 years would increase LE by more than a decade for women from the United States (10.7 [95% UI 8.4 to 12.3] years) and men (13.0 [95% UI 9.4 to 14.3] years). The largest gains would be made by eating more legumes (females: 2.2 [95% UI 1.1 to 3.4]; males: 2.5 [95% UI 1.1 to 3.9]), whole grains (females: 2.0 [95% UI 1.3 to 2.7]; males: 2.3 [95% UI 1.6 to 3.0]), and nuts (females: 1.7 [95% UI 1.5 to 2.0]; males: 2.0 [95% UI 1.7 to 2.3]), and less red meat (females: 1.6 [95% UI 1.5 to 1.8]; males: 1.9 [95% UI 1.7 to 2.1]) and processed meat (females: 1.6 [95% UI 1.5 to 1.8]; males: 1.9 [95% UI 1.7 to 2.1]). Changing from a typical diet to the optimized diet at age 60 years would increase LE by 8.0 (95% UI 6.2 to 9.3) years for women and 8.8 (95% UI 6.8 to 10.0) years for men, and 80-year-olds would gain 3.4 years (95% UI females: 2.6 to 3.8/males: 2.7 to 3.9). Change from typical to feasibility approach diet would increase LE by 6.2 (95% UI 3.5 to 8.1) years for 20-year-old women from the United States and 7.3 (95% UI 4.7 to 9.5) years for men. Using NutriGrade, the overall quality of evidence was assessed as moderate. The methodology provides population estimates under given assumptions and is not meant as individualized forecasting, with study limitations that include uncertainty for time to achieve full effects, the effect of eggs, white meat, and oils, individual variation in protective and risk factors, uncertainties for future development of medical treatments; and changes in lifestyle.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;A sustained dietary change may give substantial health gains for people of all ages both for optimized and feasible changes. Gains are predicted to be larger the earlier the dietary chan","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":"19 2","pages":"e1003889"},"PeriodicalIF":15.8,"publicationDate":"2022-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39603400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 41
Association of ischemic stroke onset time with presenting severity, acute progression, and long-term outcome: A cohort study. 缺血性脑卒中发病时间与表现严重程度、急性进展和长期结果的关联:一项队列研究。
IF 15.8 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-02-04 eCollection Date: 2022-02-01 DOI: 10.1371/journal.pmed.1003910
Wi-Sun Ryu, Keun-Sik Hong, Sang-Wuk Jeong, Jung E Park, Beom Joon Kim, Joon-Tae Kim, Kyung Bok Lee, Tai Hwan Park, Sang-Soon Park, Jong-Moo Park, Kyusik Kang, Yong-Jin Cho, Hong-Kyun Park, Byung-Chul Lee, Kyung-Ho Yu, Mi Sun Oh, Soo Joo Lee, Jae Guk Kim, Jae-Kwan Cha, Dae-Hyun Kim, Jun Lee, Moon-Ku Han, Man Seok Park, Kang-Ho Choi, Juneyoung Lee, Jeffrey L Saver, Eng H Lo, Hee-Joon Bae, Dong-Eog Kim

Background: Preclinical data suggest circadian variation in ischemic stroke progression, with more active cell death and infarct growth in rodent models with inactive phase (daytime) than active phase (nighttime) stroke onset. We aimed to examine the association of stroke onset time with presenting severity, early neurological deterioration (END), and long-term functional outcome in human ischemic stroke.

Methods and findings: In a Korean nationwide multicenter observational cohort study from May 2011 to July 2020, we assessed circadian effects on initial stroke severity (National Institutes of Health Stroke Scale [NIHSS] score at admission), END, and favorable functional outcome (3-month modified Rankin Scale [mRS] score 0 to 2 versus 3 to 6). We included 17,461 consecutive patients with witnessed ischemic stroke within 6 hours of onset. Stroke onset time was divided into 2 groups (day-onset [06:00 to 18:00] versus night-onset [18:00 to 06:00]) and into 6 groups by 4-hour intervals. We used mixed-effects ordered or logistic regression models while accounting for clustering by hospitals. Mean age was 66.9 (SD 13.4) years, and 6,900 (39.5%) were women. END occurred in 2,219 (12.7%) patients. After adjusting for covariates including age, sex, previous stroke, prestroke mRS score, admission NIHSS score, hypertension, diabetes, hyperlipidemia, smoking, atrial fibrillation, prestroke antiplatelet use, prestroke statin use, revascularization, season of stroke onset, and time from onset to hospital arrival, night-onset stroke was more prone to END (adjusted incidence 14.4% versus 12.8%, p = 0.006) and had a lower likelihood of favorable outcome (adjusted odds ratio, 0.88 [95% CI, 0.79 to 0.98]; p = 0.03) compared with day-onset stroke. When stroke onset times were grouped by 4-hour intervals, a monotonic gradient in presenting NIHSS score was noted, rising from a nadir in 06:00 to 10:00 to a peak in 02:00 to 06:00. The 18:00 to 22:00 and 22:00 to 02:00 onset stroke patients were more likely to experience END than the 06:00 to 10:00 onset stroke patients. At 3 months, there was a monotonic gradient in the rate of favorable functional outcome, falling from a peak at 06:00 to 10:00 to a nadir at 22:00 to 02:00. Study limitations include the lack of information on sleep disorders and patient work/activity schedules.

Conclusions: Night-onset strokes, compared with day-onset strokes, are associated with higher presenting neurologic severity, more frequent END, and worse 3-month functional outcome. These findings suggest that circadian time of onset is an important additional variable for inclusion in epidemiologic natural history studies and in treatment trials of neuroprotective and reperfusion agents for acute ischemic stroke.

背景:临床前数据表明缺血性卒中进展的昼夜变化,在啮齿类动物模型中,非活动期(白天)比活动期(夜间)卒中发作的活跃细胞死亡和梗死生长更多。我们的目的是研究脑卒中发作时间与人类缺血性脑卒中的表现严重程度、早期神经功能恶化(END)和长期功能结局的关系。方法和研究结果:在2011年5月至2020年7月的一项韩国全国性多中心观察性队列研究中,我们评估了昼夜节律对初始卒中严重程度(入院时国立卫生研究院卒中量表[NIHSS]评分)、END和有利的功能结局(3个月修正Rankin量表[mRS]评分0至2对3至6)的影响。我们纳入了17,461例连续发病6小时内发生缺血性卒中的患者。卒中发病时间分为2组(白天发病[06:00 ~ 18:00]和夜间发病[18:00 ~ 06:00]),每隔4小时分为6组。在考虑医院聚类时,我们使用混合效应有序或逻辑回归模型。平均年龄66.9岁(SD 13.4),女性6900人(39.5%)。2219例(12.7%)患者发生了END。在校正协变量包括年龄、性别、既往卒中、卒中前mRS评分、入院NIHSS评分、高血压、糖尿病、高脂血症、吸烟、房颤、卒中前抗血小板使用、卒中前他汀类药物使用、血运重建、卒中发作季节和从发病到住院时间后,夜间发作的卒中更容易发生END(调整发生率14.4%比12.8%,p = 0.006),并且出现良好结局的可能性较低(调整优势比0.88 [95% CI,0.79 ~ 0.98];P = 0.03)。当脑卒中发作时间按4小时间隔分组时,NIHSS评分呈现单调梯度,从06:00 - 10:00的最低点上升到02:00 - 06:00的最高点。18:00 ~ 22:00和22:00 ~ 02:00起病的脑卒中患者比06:00 ~ 10:00起病的脑卒中患者更容易发生END。在3个月时,良好的功能预后率呈单调梯度,从06:00 - 10:00的峰值下降到22:00 - 02:00的最低点。研究的局限性包括缺乏关于睡眠障碍和患者工作/活动时间表的信息。结论:与白天发作的中风相比,夜间发作的中风与更高的神经系统严重程度、更频繁的END和更差的3个月功能预后相关。这些发现表明,在流行病学自然史研究和急性缺血性卒中的神经保护和再灌注药物治疗试验中,昼夜节律的发病时间是一个重要的附加变量。
{"title":"Association of ischemic stroke onset time with presenting severity, acute progression, and long-term outcome: A cohort study.","authors":"Wi-Sun Ryu,&nbsp;Keun-Sik Hong,&nbsp;Sang-Wuk Jeong,&nbsp;Jung E Park,&nbsp;Beom Joon Kim,&nbsp;Joon-Tae Kim,&nbsp;Kyung Bok Lee,&nbsp;Tai Hwan Park,&nbsp;Sang-Soon Park,&nbsp;Jong-Moo Park,&nbsp;Kyusik Kang,&nbsp;Yong-Jin Cho,&nbsp;Hong-Kyun Park,&nbsp;Byung-Chul Lee,&nbsp;Kyung-Ho Yu,&nbsp;Mi Sun Oh,&nbsp;Soo Joo Lee,&nbsp;Jae Guk Kim,&nbsp;Jae-Kwan Cha,&nbsp;Dae-Hyun Kim,&nbsp;Jun Lee,&nbsp;Moon-Ku Han,&nbsp;Man Seok Park,&nbsp;Kang-Ho Choi,&nbsp;Juneyoung Lee,&nbsp;Jeffrey L Saver,&nbsp;Eng H Lo,&nbsp;Hee-Joon Bae,&nbsp;Dong-Eog Kim","doi":"10.1371/journal.pmed.1003910","DOIUrl":"https://doi.org/10.1371/journal.pmed.1003910","url":null,"abstract":"<p><strong>Background: </strong>Preclinical data suggest circadian variation in ischemic stroke progression, with more active cell death and infarct growth in rodent models with inactive phase (daytime) than active phase (nighttime) stroke onset. We aimed to examine the association of stroke onset time with presenting severity, early neurological deterioration (END), and long-term functional outcome in human ischemic stroke.</p><p><strong>Methods and findings: </strong>In a Korean nationwide multicenter observational cohort study from May 2011 to July 2020, we assessed circadian effects on initial stroke severity (National Institutes of Health Stroke Scale [NIHSS] score at admission), END, and favorable functional outcome (3-month modified Rankin Scale [mRS] score 0 to 2 versus 3 to 6). We included 17,461 consecutive patients with witnessed ischemic stroke within 6 hours of onset. Stroke onset time was divided into 2 groups (day-onset [06:00 to 18:00] versus night-onset [18:00 to 06:00]) and into 6 groups by 4-hour intervals. We used mixed-effects ordered or logistic regression models while accounting for clustering by hospitals. Mean age was 66.9 (SD 13.4) years, and 6,900 (39.5%) were women. END occurred in 2,219 (12.7%) patients. After adjusting for covariates including age, sex, previous stroke, prestroke mRS score, admission NIHSS score, hypertension, diabetes, hyperlipidemia, smoking, atrial fibrillation, prestroke antiplatelet use, prestroke statin use, revascularization, season of stroke onset, and time from onset to hospital arrival, night-onset stroke was more prone to END (adjusted incidence 14.4% versus 12.8%, p = 0.006) and had a lower likelihood of favorable outcome (adjusted odds ratio, 0.88 [95% CI, 0.79 to 0.98]; p = 0.03) compared with day-onset stroke. When stroke onset times were grouped by 4-hour intervals, a monotonic gradient in presenting NIHSS score was noted, rising from a nadir in 06:00 to 10:00 to a peak in 02:00 to 06:00. The 18:00 to 22:00 and 22:00 to 02:00 onset stroke patients were more likely to experience END than the 06:00 to 10:00 onset stroke patients. At 3 months, there was a monotonic gradient in the rate of favorable functional outcome, falling from a peak at 06:00 to 10:00 to a nadir at 22:00 to 02:00. Study limitations include the lack of information on sleep disorders and patient work/activity schedules.</p><p><strong>Conclusions: </strong>Night-onset strokes, compared with day-onset strokes, are associated with higher presenting neurologic severity, more frequent END, and worse 3-month functional outcome. These findings suggest that circadian time of onset is an important additional variable for inclusion in epidemiologic natural history studies and in treatment trials of neuroprotective and reperfusion agents for acute ischemic stroke.</p>","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":"19 2","pages":"e1003910"},"PeriodicalIF":15.8,"publicationDate":"2022-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39889460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
Risks of specific congenital anomalies in offspring of women with diabetes: A systematic review and meta-analysis of population-based studies including over 80 million births. 糖尿病女性后代特定先天性异常的风险:一项基于人群的研究的系统回顾和荟萃分析,包括8000多万新生儿。
IF 15.8 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-02-01 DOI: 10.1371/journal.pmed.1003900
Tie-Ning Zhang, Xin-Mei Huang, Xin-Yi Zhao, Wei Wang, Ri Wen, Shan-Yan Gao

Background: Pre-gestational diabetes mellitus (PGDM) has been known to be a risk factor for congenital heart defects (CHDs) for decades. However, the associations between maternal PGDM and gestational diabetes mellitus (GDM) and the risk of specific types of CHDs and congenital anomalies (CAs) in other systems remain under debate. We aimed to investigate type-specific CAs in offspring of women with diabetes and to examine the extent to which types of maternal diabetes are associated with increased risk of CAs in offspring.

Methods and findings: We searched PubMed and Embase from database inception to 15 October 2021 for population-based studies reporting on type-specific CAs in offspring born to women with PGDM (combined type 1 and 2) or GDM, with no limitation on language. Reviewers extracted data for relevant outcomes and performed random effects meta-analyses, subgroup analyses, and multivariable meta-regression. Risk of bias appraisal was performed using the Cochrane Risk of Bias Tool. This study was registered in PROSPERO (CRD42021229217). Primary outcomes were overall CAs and CHDs. Secondary outcomes were type-specific CAs. Overall, 59 population-based studies published from 1990 to 2021 with 80,437,056 participants met the inclusion criteria. Of the participants, 2,407,862 (3.0%) women had PGDM and 2,353,205 (2.9%) women had GDM. The meta-analyses showed increased risks of overall CAs/CHDs in offspring born to women with PGDM (for overall CAs, relative risk [RR] = 1.99, 95% CI 1.82 to 2.17, P < 0.001; for CHDs, RR = 3.46, 95% CI 2.77 to 4.32, P < 0.001) or GDM (for overall CAs, RR = 1.18, 95% CI 1.13 to 1.23, P < 0.001; for CHDs, RR = 1.50, 95% CI 1.38 to 1.64, P < 0.001). The results of the meta-regression analyses showed significant differences in RRs of CAs/CHDs in PGDM versus GDM (all P < 0.001). Of the 23 CA categories, excluding CHD-related categories, in offspring, maternal PGDM was associated with a significantly increased risk of CAs in 21 categories; the corresponding RRs ranged from 1.57 (for hypospadias, 95% CI 1.22 to 2.02) to 18.18 (for holoprosencephaly, 95% CI 4.03 to 82.06). Maternal GDM was associated with a small but significant increase in the risk of CAs in 9 categories; the corresponding RRs ranged from 1.14 (for limb reduction, 95% CI 1.06 to 1.23) to 5.70 (for heterotaxia, 95% CI 1.09 to 29.92). The main limitation of our analysis is that some high significant heterogeneity still persisted in both subgroup and sensitivity analyses.

Conclusions: In this study, we observed an increased rate of CAs in offspring of women with diabetes and noted the differences for PGDM versus GDM. The RRs of overall CAs and CHDs in offspring of women with PGDM were higher than those in offspring of women with GDM. Screening for diabetes in pregnant women may enable better glycemic control, and may enable identification of offspring at risk for CAs.

背景:数十年来,妊娠前糖尿病(PGDM)一直被认为是先天性心脏缺陷(CHDs)的危险因素。然而,母体妊娠期糖尿病和妊娠期糖尿病(GDM)与特定类型冠心病和其他系统先天性异常(CAs)风险之间的关系仍存在争议。我们的目的是研究糖尿病女性后代中特定类型的CAs,并检查哪种类型的母亲糖尿病与后代CAs风险增加相关的程度。方法和发现:我们从数据库建立到2021年10月15日检索PubMed和Embase,以人群为基础的研究报告了PGDM(合并1型和2型)或GDM妇女所生后代的类型特异性ca,没有语言限制。审稿人提取相关结果的数据,并进行随机效应荟萃分析、亚组分析和多变量荟萃回归。使用Cochrane偏倚风险评估工具进行偏倚风险评估。本研究已在PROSPERO注册(CRD42021229217)。主要结局是总ca和CHDs。次要结局为类型特异性ca。总体而言,1990年至2021年发表的59项基于人群的研究,共有80,437,056名参与者符合纳入标准。在参与者中,2407862名(3.0%)女性患有PGDM, 23353205名(2.9%)女性患有GDM。荟萃分析显示,患有PGDM的妇女所生的后代患总体CAs/CHDs的风险增加(总体CAs的相对风险[RR] = 1.99, 95% CI 1.82 ~ 2.17, P < 0.001;对于冠心病,RR = 3.46, 95% CI 2.77 ~ 4.32, P < 0.001)或GDM(对于所有ca, RR = 1.18, 95% CI 1.13 ~ 1.23, P < 0.001;冠心病的RR = 1.50, 95% CI 1.38 ~ 1.64, P < 0.001)。meta回归分析结果显示,PGDM与GDM患者CAs/CHDs的rr差异有统计学意义(均P < 0.001)。在23种CA类别中(不包括冠心病相关类别),在后代中,母体PGDM与21种CA风险显著增加相关;相应的相对危险度范围为1.57(尿道下裂,95% CI 1.22 ~ 2.02) ~ 18.18(无前脑畸形,95% CI 4.03 ~ 82.06)。孕产妇GDM与9个类别中ca风险的小幅但显著增加相关;相应的相对危险度从1.14(肢体复位,95% CI 1.06 ~ 1.23)到5.70(异位性,95% CI 1.09 ~ 29.92)不等。我们分析的主要限制是在亚组和敏感性分析中仍然存在一些高度显著的异质性。结论:在这项研究中,我们观察到糖尿病女性后代的CAs发生率增加,并注意到PGDM与GDM的差异。PGDM女性后代总体ca和CHDs的rr高于GDM女性后代。对孕妇进行糖尿病筛查可能有助于更好地控制血糖,并可能有助于识别有CAs风险的后代。
{"title":"Risks of specific congenital anomalies in offspring of women with diabetes: A systematic review and meta-analysis of population-based studies including over 80 million births.","authors":"Tie-Ning Zhang,&nbsp;Xin-Mei Huang,&nbsp;Xin-Yi Zhao,&nbsp;Wei Wang,&nbsp;Ri Wen,&nbsp;Shan-Yan Gao","doi":"10.1371/journal.pmed.1003900","DOIUrl":"https://doi.org/10.1371/journal.pmed.1003900","url":null,"abstract":"<p><strong>Background: </strong>Pre-gestational diabetes mellitus (PGDM) has been known to be a risk factor for congenital heart defects (CHDs) for decades. However, the associations between maternal PGDM and gestational diabetes mellitus (GDM) and the risk of specific types of CHDs and congenital anomalies (CAs) in other systems remain under debate. We aimed to investigate type-specific CAs in offspring of women with diabetes and to examine the extent to which types of maternal diabetes are associated with increased risk of CAs in offspring.</p><p><strong>Methods and findings: </strong>We searched PubMed and Embase from database inception to 15 October 2021 for population-based studies reporting on type-specific CAs in offspring born to women with PGDM (combined type 1 and 2) or GDM, with no limitation on language. Reviewers extracted data for relevant outcomes and performed random effects meta-analyses, subgroup analyses, and multivariable meta-regression. Risk of bias appraisal was performed using the Cochrane Risk of Bias Tool. This study was registered in PROSPERO (CRD42021229217). Primary outcomes were overall CAs and CHDs. Secondary outcomes were type-specific CAs. Overall, 59 population-based studies published from 1990 to 2021 with 80,437,056 participants met the inclusion criteria. Of the participants, 2,407,862 (3.0%) women had PGDM and 2,353,205 (2.9%) women had GDM. The meta-analyses showed increased risks of overall CAs/CHDs in offspring born to women with PGDM (for overall CAs, relative risk [RR] = 1.99, 95% CI 1.82 to 2.17, P < 0.001; for CHDs, RR = 3.46, 95% CI 2.77 to 4.32, P < 0.001) or GDM (for overall CAs, RR = 1.18, 95% CI 1.13 to 1.23, P < 0.001; for CHDs, RR = 1.50, 95% CI 1.38 to 1.64, P < 0.001). The results of the meta-regression analyses showed significant differences in RRs of CAs/CHDs in PGDM versus GDM (all P < 0.001). Of the 23 CA categories, excluding CHD-related categories, in offspring, maternal PGDM was associated with a significantly increased risk of CAs in 21 categories; the corresponding RRs ranged from 1.57 (for hypospadias, 95% CI 1.22 to 2.02) to 18.18 (for holoprosencephaly, 95% CI 4.03 to 82.06). Maternal GDM was associated with a small but significant increase in the risk of CAs in 9 categories; the corresponding RRs ranged from 1.14 (for limb reduction, 95% CI 1.06 to 1.23) to 5.70 (for heterotaxia, 95% CI 1.09 to 29.92). The main limitation of our analysis is that some high significant heterogeneity still persisted in both subgroup and sensitivity analyses.</p><p><strong>Conclusions: </strong>In this study, we observed an increased rate of CAs in offspring of women with diabetes and noted the differences for PGDM versus GDM. The RRs of overall CAs and CHDs in offspring of women with PGDM were higher than those in offspring of women with GDM. Screening for diabetes in pregnant women may enable better glycemic control, and may enable identification of offspring at risk for CAs.</p>","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":"19 2","pages":"e1003900"},"PeriodicalIF":15.8,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39878082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Evaluation of low-dose aspirin in the prevention of recurrent spontaneous preterm labour (the APRIL study): A multicentre, randomised, double-blinded, placebo-controlled trial. 低剂量阿司匹林预防复发性自发性早产的评价(APRIL研究):一项多中心、随机、双盲、安慰剂对照试验。
IF 15.8 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-02-01 DOI: 10.1371/journal.pmed.1003892
Anadeijda J E M C Landman, Marjon A de Boer, Laura Visser, Tobias A J Nijman, Marieke A C Hemels, Christiana N Naaktgeboren, Marijke C van der Weide, Ben W Mol, Judith O E H van Laar, Dimitri N M Papatsonis, Mireille N Bekker, Joris van Drongelen, Mariëlle G van Pampus, Marieke Sueters, David P van der Ham, J Marko Sikkema, Joost J Zwart, Anjoke J M Huisjes, Marloes E van Huizen, Gunilla Kleiverda, Janine Boon, Maureen T M Franssen, Wietske Hermes, Harry Visser, Christianne J M de Groot, Martijn A Oudijk
<p><strong>Background: </strong>Preterm birth is the leading cause of neonatal morbidity and mortality. The recurrence rate of spontaneous preterm birth is high, and additional preventive measures are required. Our objective was to assess the effectiveness of low-dose aspirin compared to placebo in the prevention of preterm birth in women with a previous spontaneous preterm birth.</p><p><strong>Methods and findings: </strong>We performed a parallel multicentre, randomised, double-blinded, placebo-controlled trial (the APRIL study). The study was performed in 8 tertiary and 26 secondary care hospitals in the Netherlands. We included women with a singleton pregnancy and a history of spontaneous preterm birth of a singleton between 22 and 37 weeks. Participants were randomly assigned to aspirin 80 mg daily or placebo initiated between 8 and 16 weeks of gestation and continued until 36 weeks or delivery. Randomisation was computer generated, with allocation concealment by using sequentially numbered medication containers. Participants, their healthcare providers, and researchers were blinded for treatment allocation. The primary outcome was preterm birth <37 weeks of gestation. Secondary outcomes included a composite of poor neonatal outcome (bronchopulmonary dysplasia, periventricular leukomalacia > grade 1, intraventricular hemorrhage > grade 2, necrotising enterocolitis > stage 1, retinopathy of prematurity, culture proven sepsis, or perinatal death). Analyses were performed by intention to treat. From May 31, 2016 to June 13, 2019, 406 women were randomised to aspirin (n = 204) or placebo (n = 202). A total of 387 women (81.1% of white ethnic origin, mean age 32.5 ± SD 3.8) were included in the final analysis: 194 women were allocated to aspirin and 193 to placebo. Preterm birth <37 weeks occurred in 41 (21.2%) women in the aspirin group and 49 (25.4%) in the placebo group (relative risk (RR) 0.83, 95% confidence interval (CI) 0.58 to 1.20, p = 0.32). In women with ≥80% medication adherence, preterm birth occurred in 24 (19.2%) versus 30 (24.8%) women (RR 0.77, 95% CI 0.48 to 1.25, p = 0.29). The rate of the composite of poor neonatal outcome was 4.6% (n = 9) versus 2.6% (n = 5) (RR 1.79, 95% CI 0.61 to 5.25, p = 0.29). Among all randomised women, serious adverse events occurred in 11 out of 204 (5.4%) women allocated to aspirin and 11 out of 202 (5.4%) women allocated to placebo. None of these serious adverse events was considered to be associated with treatment allocation. The main study limitation is the underpowered sample size due to the lower than expected preterm birth rates.</p><p><strong>Conclusions: </strong>In this study, we observed that low-dose aspirin did not significantly reduce the preterm birth rate in women with a previous spontaneous preterm birth. However, a modest reduction of preterm birth with aspirin cannot be ruled out. Further research is required to determine a possible beneficial effect of low-dose aspirin for women w
背景:早产是新生儿发病和死亡的主要原因。自发性早产的复发率很高,因此需要额外的预防措施。我们的目的是评估小剂量阿司匹林与安慰剂相比在预防曾发生过自发性早产的妇女早产方面的有效性:我们进行了一项平行多中心、随机、双盲、安慰剂对照试验(APRIL 研究)。这项研究在荷兰的 8 家三级医院和 26 家二级医院进行。研究对象包括单胎妊娠且单胎自发早产史在 22 到 37 周之间的妇女。参与者被随机分配到阿司匹林80毫克/天或安慰剂,阿司匹林在妊娠8至16周期间开始服用,并持续到妊娠36周或分娩。随机分配由计算机生成,使用顺序编号的药物容器进行分配隐藏。参与者、医护人员和研究人员在治疗分配时均为盲人。主要结果为早产 1 级、脑室出血 > 2 级、坏死性小肠结肠炎 > 1 期、早产儿视网膜病变、培养证实的败血症或围产期死亡)。分析采用意向治疗法。从2016年5月31日至2019年6月13日,406名妇女被随机分配到阿司匹林(n = 204)或安慰剂(n = 202)。共有387名妇女(81.1%为白人,平均年龄(32.5 ± SD)3.8岁)被纳入最终分析:194名妇女被分配服用阿司匹林,193名妇女被分配服用安慰剂。早产结论:在这项研究中,我们发现低剂量阿司匹林并不能显著降低曾有过自然早产的妇女的早产率。不过,不能排除阿司匹林可适度降低早产率的可能性。要确定低剂量阿司匹林对曾有过自然早产的妇女可能产生的益处,还需要进一步的研究:荷兰试验登记(NL5553、NTR5675)https://www.trialregister.nl/trial/5553。
{"title":"Evaluation of low-dose aspirin in the prevention of recurrent spontaneous preterm labour (the APRIL study): A multicentre, randomised, double-blinded, placebo-controlled trial.","authors":"Anadeijda J E M C Landman, Marjon A de Boer, Laura Visser, Tobias A J Nijman, Marieke A C Hemels, Christiana N Naaktgeboren, Marijke C van der Weide, Ben W Mol, Judith O E H van Laar, Dimitri N M Papatsonis, Mireille N Bekker, Joris van Drongelen, Mariëlle G van Pampus, Marieke Sueters, David P van der Ham, J Marko Sikkema, Joost J Zwart, Anjoke J M Huisjes, Marloes E van Huizen, Gunilla Kleiverda, Janine Boon, Maureen T M Franssen, Wietske Hermes, Harry Visser, Christianne J M de Groot, Martijn A Oudijk","doi":"10.1371/journal.pmed.1003892","DOIUrl":"10.1371/journal.pmed.1003892","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Preterm birth is the leading cause of neonatal morbidity and mortality. The recurrence rate of spontaneous preterm birth is high, and additional preventive measures are required. Our objective was to assess the effectiveness of low-dose aspirin compared to placebo in the prevention of preterm birth in women with a previous spontaneous preterm birth.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods and findings: &lt;/strong&gt;We performed a parallel multicentre, randomised, double-blinded, placebo-controlled trial (the APRIL study). The study was performed in 8 tertiary and 26 secondary care hospitals in the Netherlands. We included women with a singleton pregnancy and a history of spontaneous preterm birth of a singleton between 22 and 37 weeks. Participants were randomly assigned to aspirin 80 mg daily or placebo initiated between 8 and 16 weeks of gestation and continued until 36 weeks or delivery. Randomisation was computer generated, with allocation concealment by using sequentially numbered medication containers. Participants, their healthcare providers, and researchers were blinded for treatment allocation. The primary outcome was preterm birth &lt;37 weeks of gestation. Secondary outcomes included a composite of poor neonatal outcome (bronchopulmonary dysplasia, periventricular leukomalacia &gt; grade 1, intraventricular hemorrhage &gt; grade 2, necrotising enterocolitis &gt; stage 1, retinopathy of prematurity, culture proven sepsis, or perinatal death). Analyses were performed by intention to treat. From May 31, 2016 to June 13, 2019, 406 women were randomised to aspirin (n = 204) or placebo (n = 202). A total of 387 women (81.1% of white ethnic origin, mean age 32.5 ± SD 3.8) were included in the final analysis: 194 women were allocated to aspirin and 193 to placebo. Preterm birth &lt;37 weeks occurred in 41 (21.2%) women in the aspirin group and 49 (25.4%) in the placebo group (relative risk (RR) 0.83, 95% confidence interval (CI) 0.58 to 1.20, p = 0.32). In women with ≥80% medication adherence, preterm birth occurred in 24 (19.2%) versus 30 (24.8%) women (RR 0.77, 95% CI 0.48 to 1.25, p = 0.29). The rate of the composite of poor neonatal outcome was 4.6% (n = 9) versus 2.6% (n = 5) (RR 1.79, 95% CI 0.61 to 5.25, p = 0.29). Among all randomised women, serious adverse events occurred in 11 out of 204 (5.4%) women allocated to aspirin and 11 out of 202 (5.4%) women allocated to placebo. None of these serious adverse events was considered to be associated with treatment allocation. The main study limitation is the underpowered sample size due to the lower than expected preterm birth rates.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;In this study, we observed that low-dose aspirin did not significantly reduce the preterm birth rate in women with a previous spontaneous preterm birth. However, a modest reduction of preterm birth with aspirin cannot be ruled out. Further research is required to determine a possible beneficial effect of low-dose aspirin for women w","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":"19 2","pages":"e1003892"},"PeriodicalIF":15.8,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39754867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low-dose aspirin for the prevention of preterm birth: More questions than answers. 低剂量阿司匹林预防早产:问题多于答案。
IF 15.8 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-02-01 DOI: 10.1371/journal.pmed.1003908
Victoria Hodgetts Morton, Sarah J Stock
Preterm birth (birth before 37 weeks gestation) is the leading cause of neonatal mortality, is associated with long-term disability in survivors, and carries a substantial economic burden to healthcare and social services [1]. There is increasing interest in the use of aspirin as a preventative treatment for preterm birth. Low-dose aspirin prophylaxis is well established in women who are at high risk of hypertensive disorders in pregnancy. Meta-analysis of trial data shows that low-dose aspirin taken from early pregnancy is beneficial for reducing the incidence of preeclampsia and its associated complications, including preterm birth [2]. The majority of preterm births associated with preeclampsia are provider initiated, resulting from preterm cesarean section or induction of labour indicated by worsening maternal or fetal condition. Nevertheless, reanalyses of data from trials of aspirin to prevent preeclampsia have also shown small but statistically significant reductions in spontaneous preterm birth (preterm birth preceded by the spontaneous onset of contractions or preterm prelabour rupture of membranes) [3,4]. As spontaneous preterm births are the biggest contributor to preterm birth overall, the question of whether aspirin can be used to prevent spontaneous preterm births has arisen. There has been little data from primary trials to guide practice in this area. In an accompanying research study in PLOS Medicine, Landman and colleagues report on a randomised controlled trial designed to assess the effectiveness of low-dose aspirin in the prevention of preterm birth in women at high risk of preterm birth [5]. Women with a previous spontaneous preterm birth between 22 and 36 weeks gestation (a recognised risk factor for recurrent preterm birth) were eligible to participate in the APRIL (aspirin for the prevention of recurrent spontaneous preterm labour) trial. Participants were randomised to daily aspirin 80 mg or placebo, initiated between 8 and 16 weeks gestation, and continued until 36 weeks gestation. The primary outcome was any preterm birth before 37 weeks gestation (i.e., included both spontaneous and provider-initiated preterm births). Although a small reduction in recurrent preterm birth was observed in women taking low-dose aspirin, this was not statistically significant (21% preterm birth rate in women randomised to aspirin compared to 25% preterm birth in those randomised to placebo). Unfortunately, with 406 participants, the APRIL trial was underpowered to provide a definitive answer for the primary outcome of preterm birth. The sample size calculation for the APRIL trial was based on a potential 35% relative reduction in the rate of preterm birth (which the authors state was based on the average risk reduction in preterm birth seen in secondary analyses of other trials of aspirin), from a background rate of 36%. This background rate was derived from a trial of progesterone to prevent preterm birth which recruited participants fro
{"title":"Low-dose aspirin for the prevention of preterm birth: More questions than answers.","authors":"Victoria Hodgetts Morton,&nbsp;Sarah J Stock","doi":"10.1371/journal.pmed.1003908","DOIUrl":"10.1371/journal.pmed.1003908","url":null,"abstract":"Preterm birth (birth before 37 weeks gestation) is the leading cause of neonatal mortality, is associated with long-term disability in survivors, and carries a substantial economic burden to healthcare and social services [1]. There is increasing interest in the use of aspirin as a preventative treatment for preterm birth. Low-dose aspirin prophylaxis is well established in women who are at high risk of hypertensive disorders in pregnancy. Meta-analysis of trial data shows that low-dose aspirin taken from early pregnancy is beneficial for reducing the incidence of preeclampsia and its associated complications, including preterm birth [2]. The majority of preterm births associated with preeclampsia are provider initiated, resulting from preterm cesarean section or induction of labour indicated by worsening maternal or fetal condition. Nevertheless, reanalyses of data from trials of aspirin to prevent preeclampsia have also shown small but statistically significant reductions in spontaneous preterm birth (preterm birth preceded by the spontaneous onset of contractions or preterm prelabour rupture of membranes) [3,4]. As spontaneous preterm births are the biggest contributor to preterm birth overall, the question of whether aspirin can be used to prevent spontaneous preterm births has arisen. There has been little data from primary trials to guide practice in this area. In an accompanying research study in PLOS Medicine, Landman and colleagues report on a randomised controlled trial designed to assess the effectiveness of low-dose aspirin in the prevention of preterm birth in women at high risk of preterm birth [5]. Women with a previous spontaneous preterm birth between 22 and 36 weeks gestation (a recognised risk factor for recurrent preterm birth) were eligible to participate in the APRIL (aspirin for the prevention of recurrent spontaneous preterm labour) trial. Participants were randomised to daily aspirin 80 mg or placebo, initiated between 8 and 16 weeks gestation, and continued until 36 weeks gestation. The primary outcome was any preterm birth before 37 weeks gestation (i.e., included both spontaneous and provider-initiated preterm births). Although a small reduction in recurrent preterm birth was observed in women taking low-dose aspirin, this was not statistically significant (21% preterm birth rate in women randomised to aspirin compared to 25% preterm birth in those randomised to placebo). Unfortunately, with 406 participants, the APRIL trial was underpowered to provide a definitive answer for the primary outcome of preterm birth. The sample size calculation for the APRIL trial was based on a potential 35% relative reduction in the rate of preterm birth (which the authors state was based on the average risk reduction in preterm birth seen in secondary analyses of other trials of aspirin), from a background rate of 36%. This background rate was derived from a trial of progesterone to prevent preterm birth which recruited participants fro","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":"19 2","pages":"e1003908"},"PeriodicalIF":15.8,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39579091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The impact of pictorial health warnings on purchases of sugary drinks for children: A randomized controlled trial. 图形健康警示对儿童购买含糖饮料的影响:随机对照试验。
IF 15.8 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-02-01 DOI: 10.1371/journal.pmed.1003885
Marissa G Hall, Anna H Grummon, Isabella C A Higgins, Allison J Lazard, Carmen E Prestemon, Mirian I Avendaño-Galdamez, Lindsey Smith Taillie

Background: Pictorial warnings on tobacco products are promising for motivating behavior change, but few studies have examined pictorial warnings for sugary drinks, especially in naturalistic environments. This study aimed to examine the impact of pictorial warnings on parents' purchases of sugary drinks for their children in a naturalistic store laboratory.

Methods and findings: Parents of children ages 2 to 12 (n = 325, 25% identifying as Black, 20% Hispanic) completed a shopping task in a naturalistic store laboratory in North Carolina. Participants were randomly assigned to a pictorial warnings arm (sugary drinks displayed pictorial health warnings about type 2 diabetes and heart damage) or a control arm (sugary drinks displayed a barcode label). Parents selected 1 beverage and 1 snack for their child, as well as 1 household good; one of these items was selected for them to purchase and take home. The primary outcome was whether parents purchased a sugary drink for their child. Secondary outcomes included reactions to the trial labels, attitudes toward sugary drinks, and intentions to serve their child sugary drinks. Pictorial warnings led to a 17-percentage point reduction in purchases of sugary drinks (95% CI for reduction: 7% to 27%), with 45% of parents in the control arm buying a sugary drink for their child compared to 28% in the pictorial warning arm (p = 0.002). The impact of pictorial warnings on purchases did not differ by any of the 13 participant characteristics examined (e.g., race/ethnicity, income, education, and age of child). Pictorial warnings also led to lower calories (kcal), purchased from sugary drinks (82 kcal in the control arm versus 52 kcal in the pictorial warnings arm, p = 0.003). Moreover, pictorial warnings led to lower intentions to serve sugary drinks to their child, feeling more in control of healthy eating decisions, greater thinking about the harms of sugary drinks, stronger negative emotional reactions, greater anticipated social interactions, lower perceived healthfulness of sugary drinks for their child, and greater injunctive norms to limit sugary drinks for their child (all p < 0.05). There was no evidence of difference between trial arms on noticing of the labels, appeal of sugary drinks, perceived amount of added sugar in sugary drinks, risk perceptions, or perceived tastiness of sugary drinks (all p > 0.05).

Conclusions: Pictorial warnings reduced parents' purchases of sugary drinks for their children in this naturalistic trial. Warnings on sugary drinks are a promising policy approach to reduce sugary drink purchasing in the US.

Trial registration: The trial design, measures, power calculation, and analytic plan were registered before data collection at www.clinicaltrials.gov NCT04223687.

背景:烟草制品上的图形警示对于促使人们改变行为很有帮助,但很少有研究对含糖饮料的图形警示进行研究,尤其是在自然环境下。本研究旨在自然商店实验室中考察图形警示对家长为孩子购买含糖饮料的影响:2至12岁儿童的父母(n = 325,25%为黑人,20%为西班牙裔)在北卡罗来纳州的自然商店实验室完成了一项购物任务。参与者被随机分配到图形警告组(含糖饮料显示有关2型糖尿病和心脏损害的图形健康警告)或对照组(含糖饮料显示条形码标签)。家长为孩子选择 1 种饮料和 1 种零食,以及 1 种家庭用品;其中 1 种物品由家长购买并带回家。主要结果是家长是否为孩子购买了含糖饮料。次要结果包括对试验标签的反应、对含糖饮料的态度以及为孩子提供含糖饮料的意愿。图形警示使含糖饮料的购买量减少了 17 个百分点(95% CI 降幅:7% 至 27%),对照组中 45% 的家长为孩子购买了含糖饮料,而图形警示组中只有 28% 的家长为孩子购买了含糖饮料(P = 0.002)。图形警示对购买行为的影响在所考察的 13 个参与者特征(如种族/民族、收入、教育程度和孩子年龄)中没有任何差异。图形警示还降低了购买含糖饮料的热量(千卡)(对照组为 82 千卡,图形警示组为 52 千卡,p = 0.003)。此外,图形警示还能降低给孩子提供含糖饮料的意愿、让孩子感觉自己更能控制健康饮食的决定、让孩子更多思考含糖饮料的危害、让孩子产生更强烈的负面情绪反应、让孩子更期待社会交往、降低孩子对含糖饮料健康性的感知、提高孩子限制饮用含糖饮料的强制规范(所有 p < 0.05)。各试验组之间在标签的注意程度、含糖饮料的吸引力、对含糖饮料中添加糖量的感知、风险感知或对含糖饮料可口性的感知方面没有证据表明存在差异(均 p > 0.05):结论:在这项自然试验中,图片警告减少了家长为孩子购买含糖饮料的次数。在美国,含糖饮料警告是减少含糖饮料购买量的一种很有前景的政策方法:试验设计、措施、功率计算和分析计划在数据收集前已在 www.clinicaltrials.gov NCT04223687 上注册。
{"title":"The impact of pictorial health warnings on purchases of sugary drinks for children: A randomized controlled trial.","authors":"Marissa G Hall, Anna H Grummon, Isabella C A Higgins, Allison J Lazard, Carmen E Prestemon, Mirian I Avendaño-Galdamez, Lindsey Smith Taillie","doi":"10.1371/journal.pmed.1003885","DOIUrl":"10.1371/journal.pmed.1003885","url":null,"abstract":"<p><strong>Background: </strong>Pictorial warnings on tobacco products are promising for motivating behavior change, but few studies have examined pictorial warnings for sugary drinks, especially in naturalistic environments. This study aimed to examine the impact of pictorial warnings on parents' purchases of sugary drinks for their children in a naturalistic store laboratory.</p><p><strong>Methods and findings: </strong>Parents of children ages 2 to 12 (n = 325, 25% identifying as Black, 20% Hispanic) completed a shopping task in a naturalistic store laboratory in North Carolina. Participants were randomly assigned to a pictorial warnings arm (sugary drinks displayed pictorial health warnings about type 2 diabetes and heart damage) or a control arm (sugary drinks displayed a barcode label). Parents selected 1 beverage and 1 snack for their child, as well as 1 household good; one of these items was selected for them to purchase and take home. The primary outcome was whether parents purchased a sugary drink for their child. Secondary outcomes included reactions to the trial labels, attitudes toward sugary drinks, and intentions to serve their child sugary drinks. Pictorial warnings led to a 17-percentage point reduction in purchases of sugary drinks (95% CI for reduction: 7% to 27%), with 45% of parents in the control arm buying a sugary drink for their child compared to 28% in the pictorial warning arm (p = 0.002). The impact of pictorial warnings on purchases did not differ by any of the 13 participant characteristics examined (e.g., race/ethnicity, income, education, and age of child). Pictorial warnings also led to lower calories (kcal), purchased from sugary drinks (82 kcal in the control arm versus 52 kcal in the pictorial warnings arm, p = 0.003). Moreover, pictorial warnings led to lower intentions to serve sugary drinks to their child, feeling more in control of healthy eating decisions, greater thinking about the harms of sugary drinks, stronger negative emotional reactions, greater anticipated social interactions, lower perceived healthfulness of sugary drinks for their child, and greater injunctive norms to limit sugary drinks for their child (all p < 0.05). There was no evidence of difference between trial arms on noticing of the labels, appeal of sugary drinks, perceived amount of added sugar in sugary drinks, risk perceptions, or perceived tastiness of sugary drinks (all p > 0.05).</p><p><strong>Conclusions: </strong>Pictorial warnings reduced parents' purchases of sugary drinks for their children in this naturalistic trial. Warnings on sugary drinks are a promising policy approach to reduce sugary drink purchasing in the US.</p><p><strong>Trial registration: </strong>The trial design, measures, power calculation, and analytic plan were registered before data collection at www.clinicaltrials.gov NCT04223687.</p>","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":"19 2","pages":"e1003885"},"PeriodicalIF":15.8,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39878084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obesity and risk of female reproductive conditions: A Mendelian randomisation study. 肥胖与女性生殖系统疾病的风险:孟德尔随机研究
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-02-01 DOI: 10.1371/journal.pmed.1003679
Samvida S Venkatesh, Teresa Ferreira, Stefania Benonisdottir, Nilufer Rahmioglu, Christian M Becker, Ingrid Granne, Krina T Zondervan, Michael V Holmes, Cecilia M Lindgren, Laura B L Wittemans

Background: Obesity is observationally associated with altered risk of many female reproductive conditions. These include polycystic ovary syndrome (PCOS), abnormal uterine bleeding, endometriosis, infertility, and pregnancy-related disorders. However, the roles and mechanisms of obesity in the aetiology of reproductive disorders remain unclear. Thus, we aimed to estimate observational and genetically predicted causal associations between obesity, metabolic hormones, and female reproductive disorders.

Methods and findings: Logistic regression, generalised additive models, and Mendelian randomisation (MR) (2-sample, non-linear, and multivariable) were applied to obesity and reproductive disease data on up to 257,193 women of European ancestry in UK Biobank and publicly available genome-wide association studies (GWASs). Body mass index (BMI), waist-to-hip ratio (WHR), and WHR adjusted for BMI were observationally (odds ratios [ORs] = 1.02-1.87 per 1-SD increase in obesity trait) and genetically (ORs = 1.06-2.09) associated with uterine fibroids (UF), PCOS, heavy menstrual bleeding (HMB), and pre-eclampsia. Genetically predicted visceral adipose tissue (VAT) mass was associated with the development of HMB (OR [95% CI] per 1-kg increase in predicted VAT mass = 1.32 [1.06-1.64], P = 0.0130), PCOS (OR [95% CI] = 1.15 [1.08-1.23], P = 3.24 × 10-05), and pre-eclampsia (OR [95% CI] = 3.08 [1.98-4.79], P = 6.65 × 10-07). Increased waist circumference posed a higher genetic risk (ORs = 1.16-1.93) for the development of these disorders and UF than did increased hip circumference (ORs = 1.06-1.10). Leptin, fasting insulin, and insulin resistance each mediated between 20% and 50% of the total genetically predicted association of obesity with pre-eclampsia. Reproductive conditions clustered based on shared genetic components of their aetiological relationships with obesity. This study was limited in power by the low prevalence of female reproductive conditions among women in the UK Biobank, with little information on pre-diagnostic anthropometric traits, and by the susceptibility of MR estimates to genetic pleiotropy.

Conclusions: We found that common indices of overall and central obesity were associated with increased risks of reproductive disorders to heterogenous extents in a systematic, large-scale genetics-based analysis of the aetiological relationships between obesity and female reproductive conditions. Our results suggest the utility of exploring the mechanisms mediating the causal associations of overweight and obesity with gynaecological health to identify targets for disease prevention and treatment.

背景:据观察,肥胖与许多女性生殖疾病风险的改变有关。这些疾病包括多囊卵巢综合症(PCOS)、异常子宫出血、子宫内膜异位症、不孕症以及与妊娠相关的疾病。然而,肥胖在生殖系统疾病病因中的作用和机制仍不清楚。因此,我们旨在估计肥胖、代谢激素和女性生殖系统疾病之间的观察性和基因预测的因果关系:对英国生物库和公开全基因组关联研究(GWAS)中多达 257193 名欧洲血统女性的肥胖和生殖疾病数据应用了逻辑回归、广义加性模型和孟德尔随机化(MR)(2 样本、非线性和多变量)。体质指数(BMI)、腰臀比(WHR)和根据体质指数调整的腰臀比与子宫肌瘤(UF)、多囊卵巢综合征(PCOS)、月经过多(HMB)和先兆子痫有观察相关性(肥胖特征每增加 1 个标准差的几率比 [ORs] = 1.02-1.87)和遗传相关性(ORs = 1.06-2.09)。遗传预测的内脏脂肪组织(VAT)质量与 HMB(预测的 VAT 质量每增加 1 公斤的 OR [95% CI] = 1.32 [1.06-1.64],P = 0.0130)、多囊卵巢综合征(OR [95% CI] = 1.15 [1.08-1.23],P = 3.24 × 10-05)和子痫前期(OR [95% CI] = 3.08 [1.98-4.79],P = 6.65 × 10-07)的发生有关。与臀围增加(ORs = 1.06-1.10)相比,腰围增加对这些疾病和 UF 的遗传风险更高(ORs = 1.16-1.93)。瘦素、空腹胰岛素和胰岛素抵抗在肥胖与先兆子痫的遗传预测关联中各占20%至50%。生殖系统疾病根据其与肥胖的病因学关系中共同的遗传成分进行分组。由于英国生物库中女性生殖系统疾病的发病率较低,且诊断前人体测量特征的信息较少,再加上MR估计值易受遗传多效性的影响,因此这项研究的有效性受到了限制:我们发现,在对肥胖与女性生殖疾病之间的病因关系进行系统、大规模的遗传学分析时,整体肥胖和中心肥胖的常见指数与生殖疾病风险的增加有着不同程度的相关性。我们的研究结果表明,探索超重和肥胖与妇科健康之间的因果关系的中介机制,对于确定疾病预防和治疗目标非常有用。
{"title":"Obesity and risk of female reproductive conditions: A Mendelian randomisation study.","authors":"Samvida S Venkatesh, Teresa Ferreira, Stefania Benonisdottir, Nilufer Rahmioglu, Christian M Becker, Ingrid Granne, Krina T Zondervan, Michael V Holmes, Cecilia M Lindgren, Laura B L Wittemans","doi":"10.1371/journal.pmed.1003679","DOIUrl":"10.1371/journal.pmed.1003679","url":null,"abstract":"<p><strong>Background: </strong>Obesity is observationally associated with altered risk of many female reproductive conditions. These include polycystic ovary syndrome (PCOS), abnormal uterine bleeding, endometriosis, infertility, and pregnancy-related disorders. However, the roles and mechanisms of obesity in the aetiology of reproductive disorders remain unclear. Thus, we aimed to estimate observational and genetically predicted causal associations between obesity, metabolic hormones, and female reproductive disorders.</p><p><strong>Methods and findings: </strong>Logistic regression, generalised additive models, and Mendelian randomisation (MR) (2-sample, non-linear, and multivariable) were applied to obesity and reproductive disease data on up to 257,193 women of European ancestry in UK Biobank and publicly available genome-wide association studies (GWASs). Body mass index (BMI), waist-to-hip ratio (WHR), and WHR adjusted for BMI were observationally (odds ratios [ORs] = 1.02-1.87 per 1-SD increase in obesity trait) and genetically (ORs = 1.06-2.09) associated with uterine fibroids (UF), PCOS, heavy menstrual bleeding (HMB), and pre-eclampsia. Genetically predicted visceral adipose tissue (VAT) mass was associated with the development of HMB (OR [95% CI] per 1-kg increase in predicted VAT mass = 1.32 [1.06-1.64], P = 0.0130), PCOS (OR [95% CI] = 1.15 [1.08-1.23], P = 3.24 × 10-05), and pre-eclampsia (OR [95% CI] = 3.08 [1.98-4.79], P = 6.65 × 10-07). Increased waist circumference posed a higher genetic risk (ORs = 1.16-1.93) for the development of these disorders and UF than did increased hip circumference (ORs = 1.06-1.10). Leptin, fasting insulin, and insulin resistance each mediated between 20% and 50% of the total genetically predicted association of obesity with pre-eclampsia. Reproductive conditions clustered based on shared genetic components of their aetiological relationships with obesity. This study was limited in power by the low prevalence of female reproductive conditions among women in the UK Biobank, with little information on pre-diagnostic anthropometric traits, and by the susceptibility of MR estimates to genetic pleiotropy.</p><p><strong>Conclusions: </strong>We found that common indices of overall and central obesity were associated with increased risks of reproductive disorders to heterogenous extents in a systematic, large-scale genetics-based analysis of the aetiological relationships between obesity and female reproductive conditions. Our results suggest the utility of exploring the mechanisms mediating the causal associations of overweight and obesity with gynaecological health to identify targets for disease prevention and treatment.</p>","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":"19 2","pages":"e1003679"},"PeriodicalIF":10.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39878083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antidepressant discontinuation before or during pregnancy and risk of psychiatric emergency in Denmark: A population-based propensity score-matched cohort study. 在丹麦,怀孕前或怀孕期间停用抗抑郁药与精神急症风险:一项基于人口的倾向得分匹配队列研究。
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-01-31 eCollection Date: 2022-01-01 DOI: 10.1371/journal.pmed.1003895
Xiaoqin Liu, Nina Molenaar, Esben Agerbo, Natalie C Momen, Anna-Sophie Rommel, Angela Lupattelli, Veerle Bergink, Trine Munk-Olsen

Background: Women prescribed antidepressants face the dilemma of whether or not to continue their treatment during pregnancy. Currently, limited evidence is available on the efficacy of continuing versus discontinuing antidepressant treatment during pregnancy to aid their decision. We aimed to estimate whether antidepressant discontinuation before or during pregnancy was associated with an increased risk of psychiatric emergency (ascertained by psychiatric admission or emergency room visit), a proxy measure of severe exacerbation of symptoms/mental health crisis.

Methods and findings: We carried out a propensity score-matched cohort study of women who gave birth to live-born singletons between January 1, 1997 and June 30, 2016 in Denmark and who redeemed an antidepressant prescription in the 90 days before the pregnancy, identified by Anatomical Therapeutic Chemical (ATC) code N06A. We constructed 2 matched cohorts, matching each woman who discontinued antidepressants before pregnancy (N = 2,669) or during pregnancy (N = 5,467) to one who continued antidepressants based on propensity scores. Maternal characteristics and variables related to disease severity were used to generate the propensity scores in logistic regression models. We estimated hazard ratios (HRs) of psychiatric emergency in the perinatal period (pregnancy and 6 months postpartum) using stratified Cox regression. Psychiatric emergencies were observed in 76 women who discontinued antidepressants before pregnancy and 91 women who continued. There was no evidence of higher risk of psychiatric emergency among women who discontinued antidepressants before pregnancy (cumulative incidence: 2.9%, 95% confidence interval [CI]: 2.3% to 3.6% for discontinuation versus 3.4%, 95% CI: 2.8% to 4.2% for continuation; HR = 0.84, 95% CI: 0.61 to 1.16, p = 0.298). Overall, 202 women who discontinued antidepressants during pregnancy and 156 who continued had psychiatric emergencies (cumulative incidence: 5.0%, 95% CI: 4.2% to 5.9% versus 3.7%, 95% CI: 3.1% to 4.5%). Antidepressant discontinuation during pregnancy was associated with increased risk of psychiatric emergency (HR = 1.25, 95% CI: 1.00 to 1.55, p = 0.048). Study limitations include lack of information on indications for antidepressant treatment and reasons for discontinuing antidepressants.

Conclusions: In this study, we found that discontinuing antidepressant medication during pregnancy (but not before) is associated with an apparent increased risk of psychiatric emergency compared to continuing treatment throughout pregnancy.

背景:被处方抗抑郁药物的妇女面临着是否在怀孕期间继续接受治疗的两难选择。目前,有关孕期继续或停止抗抑郁治疗的疗效的证据有限,无法帮助她们做出决定。我们的目的是估计在怀孕前或怀孕期间停止抗抑郁治疗是否与精神科急诊(通过精神科入院或急诊就诊确定)风险的增加有关,精神科急诊是症状严重恶化/精神健康危机的替代措施:我们对1997年1月1日至2016年6月30日期间在丹麦生下活产单胎,并在怀孕前90天内兑换过抗抑郁药处方的女性进行了倾向得分匹配队列研究,这些女性通过解剖学治疗化学(ATC)代码N06A进行识别。我们构建了两个匹配队列,根据倾向得分将孕前停用抗抑郁药(2669 人)或孕期停用抗抑郁药(5467 人)的妇女与继续服用抗抑郁药的妇女进行匹配。在逻辑回归模型中,孕产妇特征和与疾病严重程度相关的变量被用来生成倾向分数。我们使用分层考克斯回归法估算了围产期(孕期和产后 6 个月)精神急症的危险比(HRs)。在怀孕前停用抗抑郁药的 76 名妇女和继续服用抗抑郁药的 91 名妇女中观察到了精神急症。没有证据表明孕前停用抗抑郁药的妇女发生精神急症的风险更高(累计发生率:停药为 2.9%,95% 置信区间 [CI]:2.3% 至 3.6%;继续用药为 3.4%,95% 置信区间:2.8% 至 4.2%;HR = 0.84,95% 置信区间:0.61 至 1.16,P = 0.298)。总体而言,202 名在怀孕期间停用抗抑郁药的妇女和 156 名继续服用抗抑郁药的妇女出现了精神急症(累计发生率为 5.0%,95% CI:2.8% 至 4.2%):5.0%,95% CI:4.2% 至 5.9%;3.7%,95% CI:3.1% 至 4.5%)。孕期停用抗抑郁药与精神急症风险增加有关(HR = 1.25,95% CI:1.00 至 1.55,p = 0.048)。研究的局限性包括缺乏有关抗抑郁治疗适应症和停用抗抑郁药原因的信息:在这项研究中,我们发现与在整个孕期继续治疗相比,在孕期(而非孕前)停止抗抑郁药物治疗与精神急症风险的明显增加有关。
{"title":"Antidepressant discontinuation before or during pregnancy and risk of psychiatric emergency in Denmark: A population-based propensity score-matched cohort study.","authors":"Xiaoqin Liu, Nina Molenaar, Esben Agerbo, Natalie C Momen, Anna-Sophie Rommel, Angela Lupattelli, Veerle Bergink, Trine Munk-Olsen","doi":"10.1371/journal.pmed.1003895","DOIUrl":"10.1371/journal.pmed.1003895","url":null,"abstract":"<p><strong>Background: </strong>Women prescribed antidepressants face the dilemma of whether or not to continue their treatment during pregnancy. Currently, limited evidence is available on the efficacy of continuing versus discontinuing antidepressant treatment during pregnancy to aid their decision. We aimed to estimate whether antidepressant discontinuation before or during pregnancy was associated with an increased risk of psychiatric emergency (ascertained by psychiatric admission or emergency room visit), a proxy measure of severe exacerbation of symptoms/mental health crisis.</p><p><strong>Methods and findings: </strong>We carried out a propensity score-matched cohort study of women who gave birth to live-born singletons between January 1, 1997 and June 30, 2016 in Denmark and who redeemed an antidepressant prescription in the 90 days before the pregnancy, identified by Anatomical Therapeutic Chemical (ATC) code N06A. We constructed 2 matched cohorts, matching each woman who discontinued antidepressants before pregnancy (N = 2,669) or during pregnancy (N = 5,467) to one who continued antidepressants based on propensity scores. Maternal characteristics and variables related to disease severity were used to generate the propensity scores in logistic regression models. We estimated hazard ratios (HRs) of psychiatric emergency in the perinatal period (pregnancy and 6 months postpartum) using stratified Cox regression. Psychiatric emergencies were observed in 76 women who discontinued antidepressants before pregnancy and 91 women who continued. There was no evidence of higher risk of psychiatric emergency among women who discontinued antidepressants before pregnancy (cumulative incidence: 2.9%, 95% confidence interval [CI]: 2.3% to 3.6% for discontinuation versus 3.4%, 95% CI: 2.8% to 4.2% for continuation; HR = 0.84, 95% CI: 0.61 to 1.16, p = 0.298). Overall, 202 women who discontinued antidepressants during pregnancy and 156 who continued had psychiatric emergencies (cumulative incidence: 5.0%, 95% CI: 4.2% to 5.9% versus 3.7%, 95% CI: 3.1% to 4.5%). Antidepressant discontinuation during pregnancy was associated with increased risk of psychiatric emergency (HR = 1.25, 95% CI: 1.00 to 1.55, p = 0.048). Study limitations include lack of information on indications for antidepressant treatment and reasons for discontinuing antidepressants.</p><p><strong>Conclusions: </strong>In this study, we found that discontinuing antidepressant medication during pregnancy (but not before) is associated with an apparent increased risk of psychiatric emergency compared to continuing treatment throughout pregnancy.</p>","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":"19 1","pages":"e1003895"},"PeriodicalIF":10.5,"publicationDate":"2022-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39874998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
PLoS Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1